Detalles de la búsqueda
1.
Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.
Bioorg Med Chem
; 100: 117627, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38310752
2.
Novel quinazoline-based dual EGFR/c-Met inhibitors overcoming drug resistance for the treatment of NSCLC: Design, synthesis and anti-tumor activity.
Bioorg Chem
; 142: 106938, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37913585
3.
Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.
Bioorg Chem
; 147: 107390, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38691904
4.
Novel bioactive 2-phenyl-4-aminopyrimidine derivatives as EGFRDel19/T790M/C797S inhibitors for the treatment of non-small cell lung cancer.
Arch Pharm (Weinheim)
; 357(2): e2300460, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38009481
5.
Discovery of novel potent PI3K/mTOR dual-target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity.
Arch Pharm (Weinheim)
; 356(12): e2300403, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37840368
6.
A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer.
Int J Mol Sci
; 24(19)2023 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37834269
7.
Discovery of novel 4-arylamino-quinazoline derivatives as EGFRL858R/T790M inhibitors with the potential to inhibit the non-small cell lung cancers.
Bioorg Chem
; 127: 105994, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35792314
8.
Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
Bioorg Chem
; 129: 106157, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36209563
9.
Indole-Based Tubulin Inhibitors: Binding Modes and SARs Investigations.
Molecules
; 27(5)2022 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35268688
10.
Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors.
Bioorg Chem
; 112: 104848, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33819737
11.
Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety.
Molecules
; 26(10)2021 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34065165
12.
Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors.
Bioorg Med Chem
; 28(19): 115669, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32912435
13.
Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors.
Bioorg Chem
; 95: 103525, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31887474
14.
Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016-Present).
Molecules
; 25(11)2020 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32521825
15.
Bioactivatable reductive cleavage of azobenzene for controlling functional dumbbell oligodeoxynucleotides.
Bioorg Chem
; 91: 103106, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31344515
16.
Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
J Enzyme Inhib Med Chem
; 34(1): 203-217, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30835140
17.
Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3Kα Inhibitors.
Molecules
; 24(19)2019 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31547116
18.
Design and synthesis of novel pyrimido[5,4-d]pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes.
Bioorg Med Chem
; 26(14): 4080-4087, 2018 08 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30100020
19.
Synthesis and bioevaluation study of novel N-methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors.
Bioorg Med Chem
; 26(1): 245-256, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29203143
20.
Corrigendum to "Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy" [Bioorg. Chem. 129 (2022) 106157].
Bioorg Chem
; 131: 106336, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36587506